Ipamorelin
A growth hormone secretagogue studied in early human trials; not FDA-approved as a finished drug product, and its compounding eligibility has changed over time — a licensed pharmacy can confirm today's status.
What it is
Ipamorelin is a growth-hormone secretagogue — it prompts the pituitary to release growth hormone in pulses. It went through early-phase human trials decades ago for post-operative gut recovery, which were discontinued, and it was never approved as a drug.
Its regulatory story is unusually instructive: FDA placed ipamorelin in Category 2 of its interim compounding list in September 2023, then removed it in September 2024 after the nomination was withdrawn, and its eligibility has continued to be reviewed since. Translation: whether a licensed pharmacy can compound it is a moving target that only a licensed pharmacy can answer on a given day.
What researchers have actually studied it for
Growth-hormone release in early clinical research; discontinued trials in post-operative recovery. No approved indication.
How it works
Ipamorelin activates the ghrelin receptor (GHS-R) on the pituitary, triggering pulses of GH release. Its reputation for selectivity comes from early studies showing minimal spillover into cortisol, prolactin or appetite signaling at tested doses — the 'polite' member of the secretagogue family.
The molecule itself
A pentapeptide (five amino acids) ghrelin-receptor agonist — among the smallest molecules in this library, designed at Novo Nordisk for receptor selectivity: strong GH release with minimal cortisol, prolactin or appetite activation at studied doses. Short half-life; its action is a pulse by design.
Where it came from
Developed by Novo Nordisk in the 1990s during the industry's GH-secretagogue push, ipamorelin reached phase 2 for post-operative ileus before the program was dropped. Two decades later it resurfaced as the compounding world's favorite GH peptide, usually paired with CJC-1295.
The timeline
1990s
Designed in the industry's secretagogue program; selectivity documented in early pharmacology.
2000s
Phase 2 trials for post-operative ileus; program discontinued.
2010s
Adopted as compounding wellness programs' favorite GH peptide.
2023
Placed in FDA's Category 2 — compounding restricted.
2024
Removed from Category 2 after nomination withdrawal.
2026
Scheduled for FDA advisory-committee review.
What the research record actually contains
- Early clinical pharmacology: clean GH-release curves with limited cortisol/prolactin effects.
- Discontinued phase 2 work in post-operative gut motility.
- No controlled trials on muscle, fat, recovery, sleep or aging outcomes in healthy adults — the uses it's marketed for.
What could change this assessment
The 2026 committee outcome shapes its lawful availability either way; no outcome adds efficacy evidence. If eligibility solidifies, expect renewed clinic marketing — same compound, same unrun trials, cleaner paperwork.
What's known about risks
Short-term studies reported good tolerability, which marketing rounds up to 'safe.' Chronic-use safety in healthy adults — the actual wellness pattern — has never been characterized, and sustained GH/IGF-1 elevation carries theoretical risks no one has measured for this compound.
Where it stands legally
Never approved; lives in the compounding gray zone with a genuinely fluid FDA status since 2023. Prohibited in tested sport as a GH secretagogue.
Worth asking a licensed provider
- 1.What outcome are we targeting, and what evidence connects ipamorelin to it in humans?
- 2.What is its compounding eligibility today, per the pharmacy you use?
- 3.How will we monitor IGF-1 and glucose, and what's the stop rule?
Common claims, corrected
“It's the 'safe' growth peptide.”
Reality: It's the selective one in short studies — a receptor-cleanliness fact promoted into a safety claim no chronic-use data supports.
“Its legality is settled.”
Reality: Its compounding status flipped twice in twelve months and sits before an advisory committee — the definitive moving target.
Ipamorelin FAQ
Is ipamorelin FDA-approved?
No. It reached early human trials years ago and development stopped. Its availability today runs through compounding channels whose eligibility rules have changed multiple times since 2023.
What does ipamorelin do?
It stimulates pulsatile growth-hormone release from the pituitary. What that translates to in body composition for healthy adults has not been established in controlled trials — the muscle-building reputation is extrapolation.
Is ipamorelin banned in sports?
Growth-hormone secretagogues are prohibited in tested sport. Athletes subject to testing should treat ipamorelin as banned.
Does ipamorelin make you hungry like other GHRPs?
Less than GHRP-6 at studied doses — its selectivity is real — but the receptor it activates is the hunger receptor, so mild appetite effects surface for some users.
Does ipamorelin raise testosterone?
No — it acts on the GH axis, not the gonadal axis. Claims otherwise confuse hormone systems that share marketing brochures, not physiology.